Daniel O’Day is likely to joint Gilead Sciences sometime in 2019; a formal date has not been set. According to a source familiar with the matter at hand, Gilead Sciences Inc, a drugmaker, will appoint Roche Holding AG’s Daniel O’Day… Read More ›
Roche Holding AG
Roche Holding AG acquires Foundation Medicine for $2.4 billion
The strategic move will enable Roche Holding AG to add Foundation Medicine’s portfolio of drugs to its basket of cancer treatments. FMI’s molecular insights will also enable Roche to create and develop new cancer treatments. On Tuesday, Swiss drugmaker Roche… Read More ›
manageria.biz 